Developer docs
API playgroundTry for free, no card

Search company profiles

OncoDNA

Full company profile

uuid0002gct

Namestring
OncoDNA
Legal namestring
OncoDNA S.A.
Websiteurl
oncodna.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

OncoDNA S.A. is a Belgium-headquartered theranostic and genomic company specializing in precision medicine for cancer treatment, serving three primary customer segments: hospital and oncology-center clinicians, molecular pathology laboratories, and biopharma companies. The company's core offering is an integrated kit-plus-software ecosystem for comprehensive genomic profiling (CGP) of solid tumors and liquid biopsies, anchored by the CE-IVD cleared OncoDEEP Kit — a 638-gene DNA plus 20-gene RNA NGS panel covering SNVs, INDELs, CNVs, fusions, and genomic signatures (HRD, MSI, TMB) — and the OncoSELECT Kit for ctDNA liquid biopsy. These kits are bundled with OncoKDM, a cloud-based clinical interpretation platform whose knowledge database is updated nightly through automated and human-curated processes, providing actionable therapy recommendations, clinical trial matching, and reporting.

The company monetizes through four revenue streams: (i) one-time and multi-year kit sales to laboratories (OncoDEEP and OncoSELECT Kits), (ii) recurring annual subscriptions for the OncoKDM interpretation platform, (iii) professional services including send-away laboratory testing via its certified labs in Gosselies (Belgium) and Evry (France, via the 2020 IntegraGen acquisition), and (iv) pharma services spanning biomarker testing for clinical trials, precision patient enrollment, and OncoCDI Clinical Data Intelligence. Direct enterprise field sales target hospitals and reference laboratories, complemented by channel partnerships (Synlab, Berkshire and Surrey Pathology Services, NHS South East Genomic Medicine Service) and a UK partnership manager. The technology stack is platform-agnostic across Illumina, MGI DNBSEQ, and Element AVITI sequencers, with automation supported on Hamilton and Beckman Coulter liquid handlers.

Founded in 2012/2013 by Jean-Pol Detiffe, OncoDNA is venture-backed (cumulative funding approximately €35.7M including a €6.5M Series C in July 2023), operates from Gosselies (Belgium) with subsidiaries in Evry (France) and Valencia (Spain), and entered the US market in January 2021. Leadership includes CEO Dr. Bernard Courtieu (appointed January 2021), Chief Product Officer Koenraad Eycken, Chief Data Innovation Officer Gregori Ghitti, and Chairman François Blondel. The company has established clinical evidence including 92% of advanced solid cancer patients provided with treatment information and HRD validation against the PAOLA-1 cohort.

Short descriptiontext

OncoDNA is a Belgium-based precision oncology company that provides CE-IVD cleared comprehensive genomic profiling kits (OncoDEEP, OncoSELECT), liquid biopsy assays, and the OncoKDM clinical interpretation platform to hospital laboratories, reference labs, and biopharma companies across Europe, the US, and the Middle East.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersGosselies, Belgium
HQ citystring
Gosselies
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
genomic profiling services, precision oncology diagnostics, molecular diagnostic kits, clinical decision support, biomarker testing services
Industry5 codes
PRIMARYHLAGANAA
Genomics & Next-Generation Sequencing (NGS) Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAAANAD
Molecular Tumor Boards & Clinical Interpretation Services
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
NAICS code4 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories6215
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code4 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Commercial Physical & Biological Research8731
  • Services-Testing Laboratories8734
Product category
Precision Oncology Diagnostics
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model5 records
1NGS Kit Sales (OncoDEEP Kit, OncoSELECT Kit)
TypeOne Time License
Description

Sale of CE-IVD cleared library preparation and target enrichment kits to laboratories for in-house NGS-based comprehensive genomic profiling. Kits are sold with配套 software (OncoKDM) and support services.

oncodna.com
2Clinical Testing Services
TypeProfessional Services
Description

Send-away testing service using OncoDNA's own certified laboratory in Belgium for periods when customer lab workforce is unavailable or demand peaks. Covers both solid biopsy and liquid biopsy analysis.

oncodna.com
3Software as a Service (OncoKDM)
TypeSubscription Recurring
Description

Subscription-based clinical interpretation software providing variant annotation, therapy recommendations, clinical trial matching, and reporting. Updated nightly with automated knowledge querying and human scientific team review.

oncodna.com
4Pharma Services (Clinical Testing, Precision Enrollment, Clinical Data Intelligence)
TypeProfessional Services
Description

Services for biopharma companies including biomarker testing for clinical trials, patient matching to trials based on molecular profiles, and aggregated data insights for drug development.

oncodna.com
5MRD Testing for Pharma
TypeProfessional Services
Description

Molecular residual disease testing services for pharma clinical trial monitoring and companion diagnostics.

oncodna.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure
Pricing details2 tiers
1OncoDEEP Kit for laboratories
ModelUnit PricingBilling cadenceMulti-year contract
Notes

Kit pricing for laboratory purchase. Specific price points not publicly disclosed.

oncodna.com
2OncoKDM software subscription
ModelSubscriptionBilling cadenceAnnual
Notes

Annual subscription for clinical interpretation platform. Pricing not publicly disclosed.

oncodna.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 7 records shown
1OncoDEEP
Description

Comprehensive cancer biomarker test for solid tumors (solid biopsy) and the corresponding laboratory kit solution.

oncodna.com
+6 more records
Core offering1 text field

OncoDNA is a theranostic and genomic company offering a unified precision-oncology platform that combines CE-IVD NGS diagnostic kits (OncoDEEP, OncoSELECT, OncoXPLORE), CE-marked clinical decision support software (OncoKDM), and a clinical interpretation service (OncoSHARE) for laboratories, hospitals, and pharmaceutical companies. Its core business is comprehensive genomic profiling of solid tumors and hematological malignancies to guide therapy selection, while supporting pharma with biomarker discovery, clinical trial analytics, and companion diagnostic development.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 47% overall positive response to treatment in a private oncology practice following OncoDEEP molecular profiling guidance
+2 more records
Product overview1 text field

OncoDNA is a theranostic and genomic company offering a unified platform for precision oncology comprising diagnostic kits, laboratory services, and clinical decision support software. The core portfolio includes the OncoDEEP® Kit (638-gene solid tumor NGS panel with CE-IVD clearance), OncoSELECT® Kit (liquid biopsy ctDNA assay), and OncoXPLORE® (tumor-naïve profiling). These kits are complemented by the OncoKDM® interpretation platform with integrated knowledge database, OncoCDI® for clinical data intelligence, and OncoSHARE for ordering and sample management. For healthcare institutions, OncoDNA offers direct testing services (OncoDEEP, OncoSELECT, OncoFOLLOW for monitoring). Pharma partners access Clinical Testing, Precision Enrollment, and Knowledge-Driven Medicine services. The ecosystem integrates with Illumina, MGI, and Element AVITI sequencing platforms, with software connecting to Mercury analytics.

Product and service1 record
1OncoDEEP Kit
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership21 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-20
Description

OncoDNA and KU Leuven announced the commercial launch of OncoXPLORE, a tumor-naïve molecular profiling approach. OncoXPLORE enables comprehensive genomic profiling without prior tumor tissue characterization, developed through academic collaboration.

2MGI Tech (MGI)
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-10-29
Description

MGI and OncoDNA joined forces to offer laboratories a streamlined NGS workflow for implementing Comprehensive Genomic Profiling (CGP) using the OncoDEEP Kit on MGI's DNBSEQ platform. MGI provides the sequencing hardware while OncoDNA provides the kit and software. Validated on MGI DNBSEQ-G400 sequencer.

oncodna.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-10-15
Description

NHS South East Genomic Medicine Service transitioned to the OncoDEEP Kit solid tumour panel, enabling comprehensive genomic testing for oncology patients across the NHS South East region.

Strategic tierSupportingTypeGTM or Marketing PartnerAnnounced on2022-11-24
Description

Collaboration between OncoDNA and Eli Lilly Italia to broaden access to biomarker testing for thyroid cancer patients, supporting patient access to targeted therapies.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-10-19
Description

C2i Genomics and OncoDNA partnered to bring AI-powered liquid biopsy for cancer diagnostics across Europe. The partnership enables MRD (Molecular Residual Disease) testing across Europe using C2i Genomics' whole-genome sequencing platform and OncoDNA's laboratory network and CGP expertise.

6Berkshire and Surrey Pathology Services
Strategic tierSupportingTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-10-18
Description

Berkshire and Surrey Pathology Services and OncoDNA announced formation of a national tissue collection centre to facilitate private NGS testing across the UK.

oncodna.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-03-29
Description

OncoDNA and Synlab partnered to facilitate access to comprehensive biomarker testing for cancer therapy selection in Germany, leveraging Synlab's extensive pathology laboratory network.

8Bergonié Institute
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2021-12-16
Description

Bergonié Institute collaborated with OncoDNA to test the clinical utility of blood-and tissue-based biomarker tests in oncology, generating evidence for the clinical value of comprehensive genomic profiling.

oncodna.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-11-25
Description

OncoDNA provided strategic support in Radiomics' prospective clinical trial SALMON, combining radiomics analysis with molecular profiling data.

Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2021-09-30
Description

OncoDNA teamed up with SOPHiA GENETICS to enable laboratories to establish data-driven medicine as a standard of care, combining genomic analysis with SOPHiA's analytics platform.

Strategic tierSupportingTypeGTM or Marketing PartnerAnnounced on2021-09-24
Description

OncoDNA signed collaboration agreement with the European Cancer Patient Coalition on the 2020 personalised medicine awareness project to raise patient awareness of precision medicine.

Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2021-07-13
Description

Collaboration between Bayer Saudi Arabia LLC, OncoDNA, and Tamkin Al-Seha Medical to test cancer patients for rare NTRK mutations in Saudi Arabia, supporting Bayer's targeted therapy portfolio.

13Institut Jules Bordet
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2021-06-17
Description

Institut Jules Bordet collaborates with OncoDNA to explore biology of brain metastases using personalized liquid biopsy from cerebrospinal fluid, advancing understanding of metastatic brain cancer biology.

oncodna.com
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2021-04-15
Description

OncoDNA and Institut Curie tested the clinical utility of personalized liquid biopsy in head and neck cancers, generating evidence for ctDNA-based monitoring in this cancer type.

Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2021-04-07
Description

OncoDNA and myNEO joined forces to unlock the power of mRNA therapeutics by identifying tumor-specific antigens through combined genomic analysis to support personalized cancer vaccine development.

Strategic tierSupportingTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-01-07
Description

American Hospital of Paris and OncoDNA partnered to advance breast cancer patient management through comprehensive genomic profiling and precision medicine approaches.

Strategic tierCoreTypeTechnology or Integration
Description

OncoDEEP Kit is compatible with Illumina NextSeq 500/550, NextSeq 1000/2000, NovaSeq 6000, and NovaSeq X sequencers. Long-standing technology partnership for NGS sequencing platform integration.

Strategic tierCoreTypeTechnology or Integration
Description

Twist Bioscience provides hybrid capture technology used in OncoDEEP Kit for target enrichment. OncoDNA and Twist co-host educational webinars on NGS panel design and genomic signature identification. Collaboration enables optimized probe design for the 638-gene panel.

Strategic tierCoreTypeTechnology or Integration
Description

OncoDEEP Kit has been validated on the Element AVITI System, expanding the range of compatible sequencing platforms for customers.

20Beckman Coulter (Automation)
Strategic tierSupportingTypeTechnology or Integration
Description

Beckman Coulter automation solutions are supported for automated library preparation with OncoDEEP Kit, enabling laboratories to scale their CGP testing workflows.

oncodna.com
Strategic tierSupportingTypeTechnology or Integration
Description

Hamilton automated platforms are supported for automated library preparation with OncoDEEP Kit, enabling high-throughput NGS workflows in laboratory settings.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Roche-owned leader in comprehensive genomic profiling for oncology via FoundationOne CDx and FoundationOne Liquid CDx. Directly comparable to OncoDNA's OncoDEEP and OncoSELECT offerings, with similar target customers (oncologists, hospitals, pharma) and overlapping NGS CGP panel content.

TypeDirect peer
Description

US-based molecular profiling company offering comprehensive DNA/RNA sequencing plus AI-driven analytics (MI Profile, Caris Assure for MRD). Direct competitor in CGP and liquid biopsy with pharma services and biopharma partnerships analogous to OncoDNA's Precision Enrollment and OncoCDI.

3Tempus Labs
TypeDirect peer
Description

Precision medicine company combining NGS profiling (Tempus xT, xR, xF) with a large clinical and molecular database and pharma data analytics. Overlaps with OncoDNA in oncology CGP, pharma services, and clinical trial matching.

TypeDirect peer
Description

Specialist in liquid biopsy oncology testing (Guardant360 CDx, Reveal for MRD). Comparable to OncoDNA's OncoSELECT liquid biopsy and OncoFOLLOW MRD products, with similar pharma services and clinical trial focus.

TypeDirect peer
Description

Oncology-focused clinical laboratory services company offering comprehensive NGS profiling (NeoTYPE panels), IHC, and pharma services. Comparable business model as both clinical testing service provider and kit/workflow enabler to hospital labs.

TypeDirect peer
Description

Cancer genomics company offering the ImmunoID NeXT platform for tumor profiling and the NeXT Personal MRD assay. Direct competitor in NGS CGP and liquid biopsy MRD with pharma/biopharma services comparable to OncoDNA's Precision Enrollment.

TypeDirect peer
Description

Data-driven medicine platform combining NGS analytics with a global hospital network, including oncology applications. Comparable to OncoDNA's interpretation-software-plus-distributed-testing model; also an explicit collaboration partner of OncoDNA.

8Pillar Biosciences
TypeDirect peer
Description

NGS kit manufacturer focused on oncology and inherited disease panels sold to clinical laboratories. Direct competitor in the wet-lab kit layer of OncoDNA's OncoDEEP Kit offering.

TypeBroad incumbent
Description

Large life sciences tools company with a cancer diagnostics franchise (including companion diagnostic development, NGS target enrichment via SureSelect, and pathology solutions). Broader portfolio than OncoDNA but overlapping in oncology molecular profiling reagents and CDx development.

10Inivata (now part of NeoGenomics)
TypeEmerging player
Description

Liquid biopsy company with InVisionFirst-Lung and RaDaR MRD assays, now integrated into NeoGenomics. Comparable to OncoDNA's liquid biopsy ctDNA and MRD products in technology and target market.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration5 records

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

OncoDNA

Precision Oncology Diagnosticsoncodna.com

OncoDNA is a Belgium-based precision oncology company that provides CE-IVD cleared comprehensive genomic profiling kits (OncoDEEP, OncoSELECT), liquid biopsy assays, and the OncoKDM clinical interpretation platform to hospital laboratories, reference labs, and biopharma companies across Europe, the US, and the Middle East.

What OncoDNA does

OncoDNA S.A. is a Belgium-headquartered theranostic and genomic company specializing in precision medicine for cancer treatment, serving three primary customer segments: hospital and oncology-center clinicians, molecular pathology laboratories, and biopharma companies. The company's core offering is an integrated kit-plus-software ecosystem for comprehensive genomic profiling (CGP) of solid tumors and liquid biopsies, anchored by the CE-IVD cleared OncoDEEP Kit — a 638-gene DNA plus 20-gene RNA NGS panel covering SNVs, INDELs, CNVs, fusions, and genomic signatures (HRD, MSI, TMB) — and the OncoSELECT Kit for ctDNA liquid biopsy. These kits are bundled with OncoKDM, a cloud-based clinical interpretation platform whose knowledge database is updated nightly through automated and human-curated processes, providing actionable therapy recommendations, clinical trial matching, and reporting.

The company monetizes through four revenue streams: (i) one-time and multi-year kit sales to laboratories (OncoDEEP and OncoSELECT Kits), (ii) recurring annual subscriptions for the OncoKDM interpretation platform, (iii) professional services including send-away laboratory testing via its certified labs in Gosselies (Belgium) and Evry (France, via the 2020 IntegraGen acquisition), and (iv) pharma services spanning biomarker testing for clinical trials, precision patient enrollment, and OncoCDI Clinical Data Intelligence. Direct enterprise field sales target hospitals and reference laboratories, complemented by channel partnerships (Synlab, Berkshire and Surrey Pathology Services, NHS South East Genomic Medicine Service) and a UK partnership manager. The technology stack is platform-agnostic across Illumina, MGI DNBSEQ, and Element AVITI sequencers, with automation supported on Hamilton and Beckman Coulter liquid handlers.

Founded in 2012/2013 by Jean-Pol Detiffe, OncoDNA is venture-backed (cumulative funding approximately €35.7M including a €6.5M Series C in July 2023), operates from Gosselies (Belgium) with subsidiaries in Evry (France) and Valencia (Spain), and entered the US market in January 2021. Leadership includes CEO Dr. Bernard Courtieu (appointed January 2021), Chief Product Officer Koenraad Eycken, Chief Data Innovation Officer Gregori Ghitti, and Chairman François Blondel. The company has established clinical evidence including 92% of advanced solid cancer patients provided with treatment information and HRD validation against the PAOLA-1 cohort.

OncoDNA firmographics

Firmographics
Name
OncoDNA
Legal name
OncoDNA S.A.
Website
https://oncodna.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
51–100 employees
Short description
OncoDNA is a Belgium-based precision oncology company that provides CE-IVD cleared comprehensive genomic profiling kits (OncoDEEP, OncoSELECT), liquid biopsy assays, and the OncoKDM clinical interpretation platform to hospital laboratories, reference labs, and biopharma companies across Europe, the US, and the Middle East.
Ownership category
akta.pro rank

OncoDNA industry classification

Industry
Product category
Precision Oncology Diagnostics
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)
akta.pro industry
PRIMARYHLAGANAA
Genomics & Next-Generation Sequencing (NGS) Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAAANAD
Molecular Tumor Boards & Clinical Interpretation Services
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

Keywords

  • Genomic profiling services
  • Precision oncology diagnostics
  • Molecular diagnostic kits
  • Clinical decision support
  • Biomarker testing services

Where OncoDNA is headquartered

Location

Headquarters

HQ city
Gosselies
HQ country
Belgium
HQ region
Europe

Offices4 records

Markets served

OncoDNA business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. NGS Kit Sales (OncoDEEP Kit, OncoSELECT Kit): Sale of CE-IVD cleared library preparation and target enrichment kits to laboratories for in-house NGS-based comprehensive genomic profiling. Kits are sold with配套 software (OncoKDM) and support services.
  2. Clinical Testing Services: Send-away testing service using OncoDNA's own certified laboratory in Belgium for periods when customer lab workforce is unavailable or demand peaks. Covers both solid biopsy and liquid biopsy analysis.
  3. Software as a Service (OncoKDM): Subscription-based clinical interpretation software providing variant annotation, therapy recommendations, clinical trial matching, and reporting. Updated nightly with automated knowledge querying and human scientific team review.
  4. Pharma Services (Clinical Testing, Precision Enrollment, Clinical Data Intelligence): Services for biopharma companies including biomarker testing for clinical trials, patient matching to trials based on molecular profiles, and aggregated data insights for drug development.
  5. MRD Testing for Pharma: Molecular residual disease testing services for pharma clinical trial monitoring and companion diagnostics.

Pricing tiers

ModelBillingPrice
Unit PricingMulti-year contractOncoDEEP Kit for laboratories
SubscriptionAnnualOncoKDM software subscription

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

OncoDNA product offering

Product offering

Core offering

OncoDNA is a theranostic and genomic company offering a unified precision-oncology platform that combines CE-IVD NGS diagnostic kits (OncoDEEP, OncoSELECT, OncoXPLORE), CE-marked clinical decision support software (OncoKDM), and a clinical interpretation service (OncoSHARE) for laboratories, hospitals, and pharmaceutical companies. Its core business is comprehensive genomic profiling of solid tumors and hematological malignancies to guide therapy selection, while supporting pharma with biomarker discovery, clinical trial analytics, and companion diagnostic development.

Product overview

OncoDNA is a theranostic and genomic company offering a unified platform for precision oncology comprising diagnostic kits, laboratory services, and clinical decision support software. The core portfolio includes the OncoDEEP® Kit (638-gene solid tumor NGS panel with CE-IVD clearance), OncoSELECT® Kit (liquid biopsy ctDNA assay), and OncoXPLORE® (tumor-naïve profiling). These kits are complemented by the OncoKDM® interpretation platform with integrated knowledge database, OncoCDI® for clinical data intelligence, and OncoSHARE for ordering and sample management. For healthcare institutions, OncoDNA offers direct testing services (OncoDEEP, OncoSELECT, OncoFOLLOW for monitoring). Pharma partners access Clinical Testing, Precision Enrollment, and Knowledge-Driven Medicine services. The ecosystem integrates with Illumina, MGI, and Element AVITI sequencing platforms, with software connecting to Mercury analytics.

Differentiator

Problem solved

Functional benefit

Brands

  • OncoDEEP: Comprehensive cancer biomarker test for solid tumors (solid biopsy) and the corresponding laboratory kit solution.
  • OncoSELECT
  • OncoXPLORE
  • OncoKDM
  • OncoCDI
  • OncoFOLLOW
  • OncoSHARE

Products and services

  • OncoDEEP Kit

Quantifiable outcome

  • 47% overall positive response to treatment in a private oncology practice following OncoDEEP molecular profiling guidance
  • +2 more outcomes

Companies that use OncoDNA

Customer profile

Named customers7 records

Segments3 records

Ideal customer profiles3 records

OncoDNA technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability5 records

Feature8 records

OncoDNA partnerships and signals

Strategic signal

Partnerships

21 partnerships are on record, tiered core, supporting and minor.

  • KU LeuvencoreStrategic or Co-development Partner · 20 January 2026OncoDNA and KU Leuven announced the commercial launch of OncoXPLORE, a tumor-naïve molecular profiling approach. OncoXPLORE enables comprehensive genomic profiling without prior tumor tissue characterization, developed through academic collaboration.
  • MGI Tech (MGI)coreTechnology or Integration · 29 October 2024MGI and OncoDNA joined forces to offer laboratories a streamlined NGS workflow for implementing Comprehensive Genomic Profiling (CGP) using the OncoDEEP Kit on MGI's DNBSEQ platform. MGI provides the sequencing hardware while OncoDNA provides the kit and software. Validated on MGI DNBSEQ-G400 sequencer.
  • NHS South East Genomic Medicine ServicecoreChannel Partner/ Reseller/ Distributor · 15 October 2024NHS South East Genomic Medicine Service transitioned to the OncoDEEP Kit solid tumour panel, enabling comprehensive genomic testing for oncology patients across the NHS South East region.
  • Eli Lilly ItaliasupportingGTM or Marketing Partner · 24 November 2022Collaboration between OncoDNA and Eli Lilly Italia to broaden access to biomarker testing for thyroid cancer patients, supporting patient access to targeted therapies.
  • C2i GenomicscoreStrategic or Co-development Partner · 19 October 2022C2i Genomics and OncoDNA partnered to bring AI-powered liquid biopsy for cancer diagnostics across Europe. The partnership enables MRD (Molecular Residual Disease) testing across Europe using C2i Genomics' whole-genome sequencing platform and OncoDNA's laboratory network and CGP expertise.
  • Berkshire and Surrey Pathology ServicessupportingChannel Partner/ Reseller/ Distributor · 18 October 2022Berkshire and Surrey Pathology Services and OncoDNA announced formation of a national tissue collection centre to facilitate private NGS testing across the UK.
  • SynlabcoreChannel Partner/ Reseller/ Distributor · 29 March 2022OncoDNA and Synlab partnered to facilitate access to comprehensive biomarker testing for cancer therapy selection in Germany, leveraging Synlab's extensive pathology laboratory network.
  • Bergonié InstitutesupportingStrategic or Co-development Partner · 16 December 2021Bergonié Institute collaborated with OncoDNA to test the clinical utility of blood-and tissue-based biomarker tests in oncology, generating evidence for the clinical value of comprehensive genomic profiling.
  • RadiomicsminorStrategic or Co-development Partner · 25 November 2021OncoDNA provided strategic support in Radiomics' prospective clinical trial SALMON, combining radiomics analysis with molecular profiling data.
  • SOPHiA GENETICSsupportingStrategic or Co-development Partner · 30 September 2021OncoDNA teamed up with SOPHiA GENETICS to enable laboratories to establish data-driven medicine as a standard of care, combining genomic analysis with SOPHiA's analytics platform.
  • European Cancer Patient CoalitionsupportingGTM or Marketing Partner · 24 September 2021OncoDNA signed collaboration agreement with the European Cancer Patient Coalition on the 2020 personalised medicine awareness project to raise patient awareness of precision medicine.
  • Bayer Saudi Arabia LLCsupportingStrategic or Co-development Partner · 13 July 2021Collaboration between Bayer Saudi Arabia LLC, OncoDNA, and Tamkin Al-Seha Medical to test cancer patients for rare NTRK mutations in Saudi Arabia, supporting Bayer's targeted therapy portfolio.
  • Institut Jules BordetsupportingStrategic or Co-development Partner · 17 June 2021Institut Jules Bordet collaborates with OncoDNA to explore biology of brain metastases using personalized liquid biopsy from cerebrospinal fluid, advancing understanding of metastatic brain cancer biology.
  • Institut CuriesupportingStrategic or Co-development Partner · 15 April 2021OncoDNA and Institut Curie tested the clinical utility of personalized liquid biopsy in head and neck cancers, generating evidence for ctDNA-based monitoring in this cancer type.
  • myNEOsupportingStrategic or Co-development Partner · 7 April 2021OncoDNA and myNEO joined forces to unlock the power of mRNA therapeutics by identifying tumor-specific antigens through combined genomic analysis to support personalized cancer vaccine development.
  • American Hospital of ParissupportingChannel Partner/ Reseller/ Distributor · 7 January 2021American Hospital of Paris and OncoDNA partnered to advance breast cancer patient management through comprehensive genomic profiling and precision medicine approaches.
  • IlluminacoreTechnology or IntegrationOncoDEEP Kit is compatible with Illumina NextSeq 500/550, NextSeq 1000/2000, NovaSeq 6000, and NovaSeq X sequencers. Long-standing technology partnership for NGS sequencing platform integration.
  • Twist BiosciencecoreTechnology or IntegrationTwist Bioscience provides hybrid capture technology used in OncoDEEP Kit for target enrichment. OncoDNA and Twist co-host educational webinars on NGS panel design and genomic signature identification. Collaboration enables optimized probe design for the 638-gene panel.
  • Element BiosciencescoreTechnology or IntegrationOncoDEEP Kit has been validated on the Element AVITI System, expanding the range of compatible sequencing platforms for customers.
  • Beckman Coulter (Automation)supportingTechnology or IntegrationBeckman Coulter automation solutions are supported for automated library preparation with OncoDEEP Kit, enabling laboratories to scale their CGP testing workflows.
  • Hamilton (Automation)supportingTechnology or IntegrationHamilton automated platforms are supported for automated library preparation with OncoDEEP Kit, enabling high-throughput NGS workflows in laboratory settings.

Scale indicators5 records

Recent moves8 records

Expansion highlights7 records

OncoDNA competitors and assessment

Company assessment

Direct peers

  • Foundation Medicine: Roche-owned leader in comprehensive genomic profiling for oncology via FoundationOne CDx and FoundationOne Liquid CDx. Directly comparable to OncoDNA's OncoDEEP and OncoSELECT offerings, with similar target customers (oncologists, hospitals, pharma) and overlapping NGS CGP panel content.
  • Caris Life Sciences: US-based molecular profiling company offering comprehensive DNA/RNA sequencing plus AI-driven analytics (MI Profile, Caris Assure for MRD). Direct competitor in CGP and liquid biopsy with pharma services and biopharma partnerships analogous to OncoDNA's Precision Enrollment and OncoCDI.
  • Tempus Labs: Precision medicine company combining NGS profiling (Tempus xT, xR, xF) with a large clinical and molecular database and pharma data analytics. Overlaps with OncoDNA in oncology CGP, pharma services, and clinical trial matching.
  • Guardant Health: Specialist in liquid biopsy oncology testing (Guardant360 CDx, Reveal for MRD). Comparable to OncoDNA's OncoSELECT liquid biopsy and OncoFOLLOW MRD products, with similar pharma services and clinical trial focus.
  • NeoGenomics: Oncology-focused clinical laboratory services company offering comprehensive NGS profiling (NeoTYPE panels), IHC, and pharma services. Comparable business model as both clinical testing service provider and kit/workflow enabler to hospital labs.
  • Personalis: Cancer genomics company offering the ImmunoID NeXT platform for tumor profiling and the NeXT Personal MRD assay. Direct competitor in NGS CGP and liquid biopsy MRD with pharma/biopharma services comparable to OncoDNA's Precision Enrollment.
  • SOPHiA GENETICS: Data-driven medicine platform combining NGS analytics with a global hospital network, including oncology applications. Comparable to OncoDNA's interpretation-software-plus-distributed-testing model; also an explicit collaboration partner of OncoDNA.
  • Pillar Biosciences: NGS kit manufacturer focused on oncology and inherited disease panels sold to clinical laboratories. Direct competitor in the wet-lab kit layer of OncoDNA's OncoDEEP Kit offering.

Broad incumbents

  • Agilent Technologies (Diagnostics): Large life sciences tools company with a cancer diagnostics franchise (including companion diagnostic development, NGS target enrichment via SureSelect, and pathology solutions). Broader portfolio than OncoDNA but overlapping in oncology molecular profiling reagents and CDx development.

Emerging players

  • Inivata (now part of NeoGenomics): Liquid biopsy company with InVisionFirst-Lung and RaDaR MRD assays, now integrated into NeoGenomics. Comparable to OncoDNA's liquid biopsy ctDNA and MRD products in technology and target market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

OncoDNA social profiles

Digital presence

OncoDNA compliance and trust

Trust signal

Compliance3 records

OncoDNA financial estimates

Financial estimate

Revenue estimate

Valuation estimate

OncoDNA leadership team

Management profile

Number of profiles

Profiles9 records

OncoDNA subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

OncoDNA funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

OncoDNA M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OncoDNA

What does OncoDNA do?

OncoDNA is a theranostic and genomic company offering a unified precision-oncology platform that combines CE-IVD NGS diagnostic kits (OncoDEEP, OncoSELECT, OncoXPLORE), CE-marked clinical decision support software (OncoKDM), and a clinical interpretation service (OncoSHARE) for laboratories, hospitals, and pharmaceutical companies. Its core business is comprehensive genomic profiling of solid tumors and hematological malignancies to guide therapy selection, while supporting pharma with biomarker discovery, clinical trial analytics, and companion diagnostic development.

Is OncoDNA a public or private company?

OncoDNA is a private company. It is classified as venture growth investor backed and is currently operating.

When was OncoDNA founded?

OncoDNA was founded in 2013. It employs 51 to 100 people.

Where is OncoDNA based?

OncoDNA is headquartered in Gosselies, Belgium, in the Europe region.

How does OncoDNA make money?

Five revenue lines are on record. NGS Kit Sales (OncoDEEP Kit, OncoSELECT Kit) is the primary driver. The others are clinical Testing Services, software as a Service (OncoKDM), pharma Services (Clinical Testing, Precision Enrollment, Clinical Data Intelligence) and MRD Testing for Pharma.

Who are OncoDNA's main competitors?

Direct peers on record are Foundation Medicine, Caris Life Sciences, Tempus Labs, Guardant Health, NeoGenomics, Personalis, SOPHiA GENETICS and Pillar Biosciences. Agilent Technologies (Diagnostics) is listed as a broad incumbent. Inivata (now part of NeoGenomics) is listed as an emerging player.

Does OncoDNA have an API?

No public API is recorded for OncoDNA.

What industry is OncoDNA in?

OncoDNA's product category is Precision Oncology Diagnostics. Its primary akta.pro industry code is HLAGANAA, Genomics & Next-Generation Sequencing (NGS) Services, with a secondary code of HLAAALAL, Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireSaudi Arabia Genetic Testing Market and 10 Year Forecast Report 2019-2029, Featuring Anwa Medical Labs, NoorDX, Scientific Laboratories Alliance, ELAJ, Genetrack Saudi Arabia, OncoDNA and MoreThe Saudi Arabia genetic testing market was valued at USD 0.27 billion in 2023 and is projected to grow at a 9.75% CAGR to USD 0.47 billion by 2029. Diagnostic testing and biochemical testing held the largest shares, with the Northern and Central regions leading. Growth is driven by rising cancer incidence and personalized medicine demand.PR NewswireMGI Tech und OncoDNA bündeln ihre Kräfte, um Laboren einen rationalisierten NGS-Workflow für die Implementierung des Comprehensive Genomic Profiling (CGP) OncoDEEP® Kits in der klinischen Praxis anzubMGI (MGI Tech Co., Ltd.) announced a collaboration with OncoDNA, a genomics and theranostics company specializing in precision medicine for cancer and genetic diseases. The OncoDEEP® Kit's comprehensive workflow — from sequencing through secondary analysis to final NGS data interpretation via OncoKDM™ — is now fully compatible with MGI's DNBSEQ™ sequencing platforms, removing the previous single-vendor restriction on the analysis process. The partnership aims to expand technology options for laboratories and improve the quality and accuracy of Comprehensive Genomic Profiling for solid tumors, with validation results presented at the 36th European Congress of Pathology in Florence in September 2024.PR NewswireMGI Tech et OncoDNA s'associent pour offrir aux laboratoires un flux de travail NGS rationalisé pour la mise en œuvre du kit de profilage génomique complet OncoDEEP® dans la pratique cliniqueMGI Tech and OncoDNA have announced a collaboration to ensure the full compatibility of OncoDNA's OncoDEEP® genomic profiling kit with MGI's DNBSEQ™ sequencing platforms. This partnership enables laboratories to perform comprehensive solid tumor profiling using MGI technology, expanding technological options for clinical oncology. The validation of this workflow was presented at the 36th European Congress of Pathology in September.PR NewswireMGI Tech and OncoDNA join forces to offer laboratories a streamlined NGS workflow for implementing Comprehensive Genomic Profiling (CGP) OncoDEEP® Kit in clinical practiceMGI Tech and OncoDNA announced a collaboration on October 29, 2024, making the OncoDEEP® Kit (a Comprehensive Genomic Profiling tool for solid tumor analysis) fully compatible with MGI's DNBSEQ™ sequencing platforms. Previously limited to a single sequencing technology provider, the partnership expands laboratory access to precision oncology solutions by combining OncoDNA's 638-gene CGP panel with MGI's sequencers. The collaboration was underscored by presentation of validation results at the 36th European Congress of Pathology in Florence.PR NewswireThe Global Cancer Biomarkers Market to Upsurge at a Tremendous CAGR of ~14% by 2027 | DelveInsightDelveInsight's Cancer Biomarkers Market Insights report projects the global cancer biomarkers market will grow at a CAGR of approximately 14% during the forecast period (2019–2027), driven by rising cancer prevalence, increasing risk factors, and new product launches with regulatory approvals. North America is expected to dominate the market through 2027. Notable recent developments include FDA 510(k) clearance granted to Biovica International's Divitum Tka assay for metastatic breast cancer monitoring, collaborations such as AstraZeneca and Roche's partnership in the Middle East and North Africa, and various product launches by companies including Lunit, Guardant Health, EDX Medical Group, and OncoDNA.GlobeNewswireOncoDNA appoints Dr Bernard Courtieuas Chief Executive OfficerOncoDNA appointed Bernard Courtieu, former IntegraGen CEO, as its Chief Executive Officer, with Jean-Pol Detiffe named Chief Strategic & Innovation Officer. The move follows the friendly takeover of IntegraGen, creating a European group with over 100 employees and €14m in combined revenues. Eduardo Bravo, interim CEO, will remain a consultant to the Board.FinSMEsOncoDNA Closes €19M Series B Funding - FinSMEsOncoDNA, a Belgian precision medicine company, raised €19M in Series B funding led by Vesalius Biocapital III and Swisscanto Invest. The round will support international growth, software development, and hiring. The company employs 50 people and collaborates with biopharma on clinical trials.GlobeNewswireOncoDNA announces screening collaboration with Kura OncologyOncoDNA signed a screening agreement with Kura Oncology to support patient enrolment for Kura's Phase II trial of tipifarnib in HRAS mutant head and neck squamous cell carcinoma. The agreement will help identify patients who may benefit from tipifarnib, and Kura plans to initiate the AIM-HN trial in the second half of 2018.LeMagITOncoDNA s'appuie sur la solution LTFS de Nodeum pour ses archivesOncoDNA deployed Nodeum's LTFS storage solution to archive 100TB of data, combining 8TB of Flash with 92TB of tape storage. The system reduces costs and energy consumption compared to its previous IBM tape libraries, which lacked indexing and search capabilities.Computer WeeklyCancer researcher gets Nodeum LTFS tape NASOncoDNA, a Belgian cancer research organization, deployed Nodeum's flash-plus-tape linear tape file system (LTFS) archive to store 100TB of data. The system combines 8TB of flash with 92TB of tape, reducing hardware costs and power usage compared to its previous IBM tape library.